Compare · MDLN vs OSUR
MDLN vs OSUR
Side-by-side comparison of Medline Inc. (MDLN) and OraSure Technologies Inc. (OSUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and OSUR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 155.4x OSUR ($285.7M).
- Over the past year, MDLN is down 17.1% and OSUR is up 45.5% - OSUR leads by 62.5 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 7 for OSUR).
- MDLN has more recent analyst coverage (25 ratings vs 5 for OSUR).
- Company
- Medline Inc.
- OraSure Technologies Inc.
- Price
- $33.80+0.58%
- $4.16+3.23%
- Market cap
- $44.40B
- $285.7M
- 1M return
- -19.55%
- +32.48%
- 1Y return
- -17.07%
- +45.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 20
- 7
- Recent ratings
- 25
- 5
OraSure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest OSUR
- Director Mcmahon Robert W. was granted 46,106 shares, increasing direct ownership by 60% to 123,137 units (SEC Form 4)
- Director Boyd Steven Kyle was granted 46,106 shares, increasing direct ownership by 41% to 159,568 units (SEC Form 4)
- Director Marmora Lelio was granted 46,106 shares, increasing direct ownership by 45% to 148,460 units (SEC Form 4)
- Director Gagliano Nancy J was granted 46,106 shares, increasing direct ownership by 33% to 185,055 units (SEC Form 4)
- Director Bertrand John D. was granted 46,106 shares, increasing direct ownership by 137% to 79,767 units (SEC Form 4)
- Director Kenny John P. was granted 46,106 shares, increasing direct ownership by 28% to 209,714 units (SEC Form 4)
- OraSure Technologies Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Boyd Steven Kyle bought $224,750 worth of shares (75,000 units at $3.00), increasing direct ownership by 195% to 113,462 units (SEC Form 4)
- Director Bertrand John D. was granted 33,661 shares (SEC Form 4)
- SEC Form 3 filed by new insider Bertrand John D.